Girgis Reda E, Khaghani Asghar
Richard DeVos Heart and Lung Transplant Program, Spectrum Health.
Michigan State University, College of Human Medicine, Grand Rapids, MI, USA.
Glob Cardiol Sci Pract. 2016 Mar 31;2016(1):e201605. doi: 10.21542/gcsp.2016.5.
Lung transplantation has grown considerably in recent years and its availability has spread to an expanding number of countries worldwide. Importantly, survival has also steadily improved, making this an increasingly viable procedure for patients with end-stage lung disease and limited life expectancy. In this first of a series of articles, recipient selection and type of transplant operation are reviewed. Pulmonary fibrotic disorders are now the most indication in the U.S., followed by chronic obstructive pulmonary disease and cystic fibrosis. Transplant centers have liberalized criteria to include older and more critically ill candidates. A careful, systematic, multi-disciplinary selection process is critical in identifying potential barriers that may increase risk and optimize long-term outcomes.
近年来，肺移植有了显著发展，其可及性已扩展到全球越来越多的国家。重要的是，肺移植患者的生存率也在稳步提高，这使得肺移植对于终末期肺病且预期寿命有限的患者而言，日益成为一种可行的治疗手段。在本系列文章的第一篇中，将对肺移植受者的选择及移植手术类型进行综述。目前，在美国，肺移植最常见的适应证是肺纤维化疾病，其次是慢性阻塞性肺疾病和囊性纤维化。移植中心放宽了标准，将年龄较大及病情更危重的患者纳入其中。一个细致、系统的多学科选择过程对于识别可能增加风险的潜在障碍以及优化长期治疗效果至关重要。
